Pure Global AI
NCT05992402Not yet recruiting

Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery

Kayela ArrottaClinicalTrials.govbehavioral
Verified
Study focus
Disease/Condition
Epilepsy
Drug/Device/Intervention
ReBOOT program
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Kayela Arrotta
Funder
The Cleveland Clinic
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Jun 01, 2028
Enrollment
150 participants
Primary outcome

Recruitment success,Intervention attendance,Rate of Homework Completion,Study Attrition,Intervention Efficacy based on Functional Status - Based on The Instrumental Activities of Daily Living-Compensation questionnaire score,Intervention Efficacy based on Functional Status - Based on The Quality of Life in Epilepsy questionnaire score

Summary

The goal of this clinical trial is to learn if new educational program prior to epilepsy
 surgery can either decrease the risk of cognitive decline after surgery or be a help to those
 patients who experience a decline after undergoing epilepsy surgery.
 
 Participants will participate in 2 individual virtual sessions and 4 virtual group sessions
 over the course of 5-6 weeks prior to their epilepsy surgery. They will asked to fill out
 online surveys and questionnaires at various times throughout the study, up to 12 months
 after their surgery.
 
 To see if the educational program works, researchers will compare those participating in the
 educational program with those that are receiving the standard epilepsy care prior to
 surgery.

ICD-10 classifications
EpilepsyEpilepsy, unspecifiedOther epilepsyStatus epilepticusOther status epilepticus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05992402
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05992402 through Pure Global AI's free database. This phase not specified trial is sponsored by Kayela Arrotta and is currently Not yet recruiting. The study focuses on Epilepsy. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.